Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With Autologous GM-CSF–Transduced Tumor Cells in Metastatic Melanoma Patients
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Purpose: To determine the feasibility, toxicity, and immunologic effects of vaccination with autologous tumor cells retrovirally transduced with the GM-CSF gene, we performed a phase I/II vaccination study in stage IV metastatic melanoma patients. Patients and Methods: Sixty-four patients were randomly assigned to receive three vaccinations of high-dose or low-dose tumor cells at 3-week intervals. Tumor cell vaccine preparation succeeded for 56 patients (88%), but because of progressive disease, the well-tolerated vaccination was completed in only 28 patients. We analyzed the priming of T cells against melanoma antigens, MART-1, tyrosinase, gp100, MAGE-A1, and MAGE-A3 using human leukocyte antigen/peptide tetramers and functional assays. Results: The high-dose vaccination induced the infiltration of T cells into the tumor tissue. Three of 14 patients receiving the high-dose vaccine showed an increase in MART-1– or gp100-specific T cells in the peripheral blood during vaccination. Six patients experienced disease-free survival for more than 5 years, and two of these patients developed vitiligo at multiple sites after vaccination. MART-1– and gp100-specific T cells were found infiltrating in vitiligo skin. Upon vaccination, the T cells acquired an effector phenotype and produced interferon-γ on specific antigenic stimulation. Conclusion: We conclude that vaccination with GM-CSF–transduced autologous tumor cells has limited toxicity and can enhance T-cell activation against melanocyte differentiation antigens, which can lead to vitiligo. Whether the induction of autoimmune vitiligo may prolong disease-free survival of metastatic melanoma patients who are surgically rendered as having no evidence of disease before vaccination is worthy of further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“Soluble allophycocyanin (APC) -labeled HLA/peptide tetramers were produced as described previously.(22)”
MethodCancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575 · cited 1×
“tion enhanced breakage of tolerance to the gp100 antigen, resulting in melanoma regression and vitiligo.(32) In the 0.”
Chapman, P. B., Wu, D., Ragupathi, G., Lu, S., Williams, L., Hwu, W.-J., Johnson, D., & Livingston, P. O. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0345 · Cited by 70
Cited by
Hypopigmenting agents: an updated review on biological, chemical and clinical aspects
Solano, F., Briganti, S., Picardo, M., & Ghanem, G. (2006) · Pigment Cell Research · doi:10.1111/j.1600-0749.2006.00334.x · Cited by 696
Teulings, H.-E., Limpens, J., Jansen, S. N., Zwinderman, A. H., Reitsma, J. B., Spuls, P. I., & Luiten, R. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4756 · Cited by 625
Self-citation(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00007-1 · Cited by 594
GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation
Becher, B., Tugues, S., & Greter, M. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.026 · Cited by 593
Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients
van den Boorn, J. G., Konijnenberg, D., Dellemijn, T. A. M., Wietze van der Veen, J. P., Bos, J. D., Melief, C. J. M., Vyth-Dreese, F. A., & Luiten, R. M. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.32 · Cited by 543
Self-citationImmunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H., Kalinski, P., & Ferrone, S. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 436
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
Drake, C. G., Lipson, E. J., & Brahmer, J. R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.208 · Cited by 422
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
Parmiani, G., Castelli, C., Pilla, L., Santinami, M., Colombo, M. P., & Rivoltini, L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl158 · Cited by 300
Therapeutic Cancer Vaccines: Current Status and Moving Forward
Schlom, J. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs033 · Cited by 282
Butterfield, L. H. (2015) · BMJ · doi:10.1136/bmj.h988 · Cited by 272
Questions asked and answered in pilot and feasibility randomized controlled trials
Shanyinde, M., Pickering, R. M., & Weatherall, M. (2011) · BMC Medical Research Methodology · doi:10.1186/1471-2288-11-117 · Cited by 229
“Using computer generated random numbers we selected 50 of those identified for full review [10-59].”
BackgroundMethodUgurel, S., Schrama, D., Keller, G., Schadendorf, D., Bröcker, E.-B., Houben, R., Zapatka, M., Fink, W., Kaufman, H. L., & Becker, J. C. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0407-z · Cited by 88
“However, response rates to immunotherapy are often low and vary among patients [19–21].”
Background
Metadata
- Authors
- Luiten, R. M., Kueter, E. W. M., Mooi, W., Gallee, M. P. W., Rankin, E. M., Gerritsen, W. R., Clift, S. M., Nooijen, W. J., Weder, P., van de Kasteele, W. F., Sein, J., van den Berk, P. C. M., Nieweg, O. E., Berns, A. M., Spits, H., & de Gast, G. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-12-10
- Volume
- 23
- Issue
- 35
- Pages
- 8978-8991
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2125200037
- Cited by
- 106
- References
- 4
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.